281 related articles for article (PubMed ID: 33941042)
1. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
Linder K; Lulla P
Hum Vaccin Immunother; 2021 Aug; 17(8):2602-2616. PubMed ID: 33941042
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
[TBL] [Abstract][Full Text] [Related]
3. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
4. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N
Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
7. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
8. Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.
Yanada M; Mizuno S; Yamasaki S; Harada K; Konuma T; Tamaki H; Shingai N; Uchida N; Ozawa Y; Tanaka M; Onizuka M; Sawa M; Nakamae H; Shiratori S; Matsuoka KI; Eto T; Kawakita T; Maruyama Y; Ichinohe T; Kanda Y; Atsuta Y; Aoki J; Yano S
Leuk Lymphoma; 2021 Dec; 62(14):3411-3419. PubMed ID: 34348554
[TBL] [Abstract][Full Text] [Related]
9. PD-1 signaling and inhibition in AML and MDS.
Haroun F; Solola SA; Nassereddine S; Tabbara I
Ann Hematol; 2017 Sep; 96(9):1441-1448. PubMed ID: 28643044
[TBL] [Abstract][Full Text] [Related]
10. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
[TBL] [Abstract][Full Text] [Related]
14. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.
Bader P; Klingebiel T; Schaudt A; Theurer-Mainka U; Handgretinger R; Lang P; Niethammer D; Beck JF
Leukemia; 1999 Dec; 13(12):2079-86. PubMed ID: 10602432
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
Spillane DR; Assouline S
Expert Rev Hematol; 2023; 16(11):819-834. PubMed ID: 37819154
[TBL] [Abstract][Full Text] [Related]
17. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
18. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.
Uy N; Singh A; Gore SD; Prebet T
Expert Opin Pharmacother; 2017 Aug; 18(12):1213-1224. PubMed ID: 28675065
[TBL] [Abstract][Full Text] [Related]
20. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
Zuanelli Brambilla C; Lobaugh SM; Ruiz JD; Dahi PB; Goldberg AD; Young JW; Gyurkocza B; Shaffer BC; Ponce DM; Tamari R; Sanchez Escamilla M; Castillo Flores N; Politikos I; Scordo M; Shah GL; Cho C; Lin RJ; Maloy MA; Devlin SM; Jakubowski AA; Berman E; Stein EM; Papadopoulos EB; Perales MA; Tallman MS; Giralt SA; Smith M
Transplant Cell Ther; 2021 Sep; 27(9):771.e1-771.e10. PubMed ID: 34033977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
